Phenylketonuria, Oxidative Stress, and BH4
This study is currently recruiting participants.
Verified June 2011 by Emory University
Sponsor:
Emory University
Information provided by:
Emory University
ClinicalTrials.gov Identifier:
NCT01395394
First received: June 23, 2011
Last updated: July 14, 2011
Last verified: June 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to see how tetrahydrobiopterin therapy (BH4; also known as sapropterin dihydrochloride or Kuvan) affects measures of oxidative stress and endothelial function in patients with Phenylketonuria (PKU).
| Condition | Intervention | Phase |
|---|---|---|
|
Phenylketonuria |
Drug: Kuvan Other: Meal Challenge |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label |
| Official Title: | The Ability of Kuvan® (Sapropterin Dihydrochloride) to Prevent Meal-induced Lipid Peroxidation and Endothelial Dysfunction in Patients With Phenylketonuria: a Pilot Study |
Resource links provided by NLM:
Genetics Home Reference related topics:
argininosuccinic aciduria
citrullinemia
N-acetylglutamate synthase deficiency
ornithine translocase deficiency
phenylketonuria
succinic semialdehyde dehydrogenase deficiency
tetrahydrobiopterin deficiency
MedlinePlus related topics:
Phenylketonuria
U.S. FDA Resources
Further study details as provided by Emory University:
Primary Outcome Measures:
- Lipid Peroxidation [ Time Frame: Lipid peroxidation will be measured every other hour for six hours at each study visit ] [ Designated as safety issue: No ]Markers will be assessed every other hour for each 6-hour study visit. Kuvan responders and healthy controls will only be assessed at one 6-hour study visit. Kuvan non-responders will be assessed at two study visits (a baseline visit, and a visit after two weeks of Kuvan therapy). Values will be assessed groupwise and also assessed for intrapersonal change in the Kuvan non-responsive group. Time frame of participation is estimated at one month.
| Estimated Enrollment: | 50 |
| Study Start Date: | June 2011 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: BH4 Non-Responders
Participants in this group have PKU and were deemed unresponsive to the drug. They will attend their first study visit, and proceed through the meal challenge without BH4. They will then take BH4 for 2 weeks. The second meal challenge will be performed with the participant's final dose of BH4.
|
Drug: Kuvan
Participants in the BH4 Non-Responder group will be given a 20 mg/kg body weight/day dose of Kuvan to take on a daily basis for two weeks. The last dose will be administered at the participant's study visit 2.
Other Names:
Other: Meal Challenge
At each study visit, patients will receive a meal high in polyunsaturated fats that will promote a transitory increase in oxidative stress measures and endothelial dysfunction
|
|
Experimental: Healthy Controls
Participants in this group match an enrolled PKU participant in terms of age, gender, and body mass index class. They will participate in a single study visit and will not be given BH4.
|
Other: Meal Challenge
At each study visit, patients will receive a meal high in polyunsaturated fats that will promote a transitory increase in oxidative stress measures and endothelial dysfunction
|
|
Experimental: BH4 Responders
Participants in this group will use their already prescribed BH4 with the meal challenge and be assessed at a single study visit. They will take their prescribed BH4 with the meal.
|
Other: Meal Challenge
At each study visit, patients will receive a meal high in polyunsaturated fats that will promote a transitory increase in oxidative stress measures and endothelial dysfunction
|
Detailed Description:
Oxidative stress will be induced by having participants eat a meal in polyunsaturated fats. The investigators will see how participants respond to the meal challenge over the course of 6 hours.
- PKU participants who are currently on BH4 therapy will be evaluated while taking BH4 with the meal at a single study visit.
- PKU participants who did not responded to BH4 therapy will be evaluated twice. At the first study visit the investigators will see how you react to the meal challenge when you are not given BH4. You will be given BH4 for two weeks, then return for a second meal challenge study visit while taking BH4.
- Healthy controls will be evaluated after consuming the meal only (no BH4) at a single study visit.
Eligibility| Ages Eligible for Study: | 10 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Have read, understood, and signed this consent form (and assent form, if <18 years old)
- Are between the ages of 10-45 years
- Weigh at least 75 pounds (34 kg)
- Meet group-specific criteria
Exclusion Criteria:
- Smoke
- Have any history of cardiovascular disease
- Have hepatic impairment, or demonstrate abnormal baseline liver function lab test results
- Have donated blood within 3 months prior to the study or are anemic as shown by the baseline lab results
- Are unwilling to discontinue dietary supplements (excluding medical food) two weeks prior to their first study visit
- Are currently take medications that will interfere with the interpretation of selected endpoints (such as lipid-lowering medication)
- Are currently pregnant or breastfeeding
- Excluding PKU, have a chronic illness, disorder, or condition (including but not limited to diabetes, hypertension, cancer)
- Have taken any investigational drug (including Kuvan for Kuvan-unresponsive participants & controls) within 3 months prior to the study
- In the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01395394
Contacts
| Contact: Meghan E. Quirk, BS | 404-778-1286 | mquirk@emory.edu |
Locations
| United States, Georgia | |
| Emory University | Recruiting |
| Decatur, Georgia, United States, 30033 | |
Sponsors and Collaborators
Emory University
Investigators
| Principal Investigator: | Rani H Singh, PhD | Emory University |
More Information
Additional Information:
No publications provided
| Responsible Party: | Rani H. Singh, PhD RD LD, Emory University |
| ClinicalTrials.gov Identifier: | NCT01395394 History of Changes |
| Other Study ID Numbers: | IRB-00046153 |
| Study First Received: | June 23, 2011 |
| Last Updated: | July 14, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Emory University:
|
Phenylketonuria PKU tetrahydrobiopterin sapropterin dihydrochloride |
BH4 Kuvan Oxidative stress |
Additional relevant MeSH terms:
|
Phenylketonurias Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Amino Acid Metabolism, Inborn Errors Metabolism, Inborn Errors Genetic Diseases, Inborn Metabolic Diseases |
ClinicalTrials.gov processed this record on May 23, 2013